In the afternoon of March 10th, Gan & Lee Pharmaceuticals(603087) announced the latest clinical progress. Its independently developed glucagon like peptide -1 receptor agonist (GLP-1) GZR18 has opened a double-blind, randomized, placebo-controlled, sequential, single dose incremental phase I trial in the United States, and the first patient has been completed. The initial indication is type 2 diabetes, which is expected to be injected once a week.
Glucagon like peptide-1 (GLP-1) has a variety of blood glucose regulating effects. For example, it can promote insulin secretion and inhibit glucagon release when blood glucose is high. Normally, these glycemic regulatory effects are impaired in patients with type 2 diabetes. Gan & Lee Pharmaceuticals(603087) said that the main purpose of this phase I clinical trial is to investigate the safety and tolerance of gzr18 in healthy subjects, and the secondary purpose is to determine the pharmacokinetic (PK) parameters of gzr18.
As the first domestic pharmaceutical enterprise to enter the high-end insulin market in Europe and the United States, Gan & Lee Pharmaceuticals(603087) as early as 2018, it signed a strategic cooperation agreement with Sandoz, a subsidiary of Novartis, an international pharmaceutical enterprise, to accelerate the expansion of overseas markets.
Gan & Lee Pharmaceuticals(603087) said that the first human administration of gzr18 in the phase I clinical trial in the United States marked the further expansion of overseas clinical pipelines.
